Japan’s Shionogi Pharmaceuticals develops oral medicines for the new coronary pneumonia (COVID-19), and has submitted an application to the Japanese government for a manufacturing and sales license in February, and has signed a basic agreement with the Japanese Ministry of Health, Labour and Welfare. 1 million people to provide oral medicine for the new crown for the treatment of mild patients.
Japanese Minister of Health, Labour and Welfare Shigeruyuki Goto said that the government has reached a consensus with Shionogi Pharmaceuticals and is waiting for the approval of the regulatory authorities. It is expected to purchase 1 million oral medicines. In the future, it will provide more treatment options for those diagnosed with mild symptoms, and in the future. After the delivery of 1 million doses of the drug, there is also a consensus that a certain amount will be continued to be purchased.
Shionogi Pharmaceutical has submitted an application to the Japanese government for a manufacturing and sales license on February 25, and is currently under review. If approved, it will become the first Japanese-made oral drug for the new crown, and it will be the first drug developed by Pfizer and Merck. Japan is the third antiviral drug approved for COVID-19.
Shionogi Pharma has global ambitions for new crown oral drugs, and with the support of the U.S. government, it is expected to start a Phase III clinical trial of new crown oral drugs worldwide, and it is expected to start a production line in April. , the target annual output provides more than 10 million servings.